Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Neurologia (Engl Ed) ; 39(6): 496-504, 2024.
Article in English | MEDLINE | ID: mdl-38901926

ABSTRACT

BACKGROUND: Despite comprehensive study, the aetiology of stroke is not identified in 35% of cases. AIMS: We conducted a study to assess the diagnostic capacity of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the identification of ischaemic stroke of cardioembolic origin. The secondary purpose of the study was to evaluate the prognostic value of NT-proBNP for predicting 90-day all-cause mortality. METHODS: We designed a prospective observational study including patients hospitalised due to stroke between March 2019 and March 2020. Blood samples were collected on admission to the emergency department and serum NT-proBNP levels were determined. Statistical analysis was performed using a bivariate logistic regression model and receiver operating characteristic (ROC) and Kaplan-Meier curves. Statistical significance was established at p<.05. RESULTS: The study included 207 patients with first ischaemic stroke. Plasma NT-proBNP levels were significantly higher (p<.001) in the cardioembolic stroke group (2069pg/mL±488.5). ROC curves showed that NT-proBNP>499pg/mL was the optimum value for diagnosing cardioembolic ischaemic stroke (sensitivity, 82%; specificity, 80%). Moreover, plasma NT-proBNP levels>499pg/mL were independently associated with cardioembolic stroke (OR: 9.881; p=.001). Finally, NT-proBNP>1500pg/mL was useful for predicting 90-day mortality (sensitivity, 70%; specificity, 93%). CONCLUSIONS: NT-proBNP was independently associated with cardioembolic stroke and should be quantified in blood tests within 24h of stroke onset. High plasma levels (>499pg/mL) may indicate an underlying cardioembolic cause, which should be further studied, while NT-proBNP >1500pg/mL was associated with increased 90-day mortality.


Subject(s)
Biomarkers , Ischemic Stroke , Natriuretic Peptide, Brain , Peptide Fragments , Humans , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Female , Male , Biomarkers/blood , Aged , Prospective Studies , Middle Aged , Ischemic Stroke/blood , Ischemic Stroke/diagnosis , Ischemic Stroke/mortality , Ischemic Stroke/complications , Embolic Stroke/blood , Embolic Stroke/diagnosis , Aged, 80 and over , Prognosis , ROC Curve
2.
Neurosci Lett ; 463(1): 37-9, 2009 Sep 29.
Article in English | MEDLINE | ID: mdl-19638294

ABSTRACT

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc). Parkinsonian patients and animal models of PD show inflammatory phenomena such as microglial activation and cytokine production that could modulate the progression of the disease, since they play a crucial role in the degenerative process. Since acute phase proteins (APPs) are involved in a number of homeostatic alterations and inflammatory processes, we analyzed the levels of APPs in primates before and after treatment with MPTP. A significant increase in C-reactive protein (CRP), serum amyloid A (SAA) and haptoglobin (HP) levels after MPTP treatment. These results demonstrate that MPTP induces a systemic generalized inflammatory reaction after specific dopaminergic neurotoxicity insult, suggesting that the inflammatory process in Parkinsonism may affect other immune-inflammatory responses outside the brain.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Acute-Phase Proteins/metabolism , Dopamine Agents , Parkinson Disease, Secondary/immunology , Animals , C-Reactive Protein/metabolism , Haptoglobins/metabolism , Inflammation/blood , Macaca fascicularis , Male , Parkinson Disease, Secondary/blood , Parkinson Disease, Secondary/chemically induced , Serum Amyloid A Protein/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...